Trazodone Monitoring Schedule: Labs & Exams Your Prescriber Should Order

How Trazodone Works: Mechanism of Action

Trazodone is a serotonin antagonist and reuptake inhibitor, commonly abbreviated SARI. It blocks the serotonin 5-HT2A receptor and inhibits the serotonin transporter (SERT), which increases serotonin availability in the synaptic cleft while dampening post-synaptic excitation. This dual action separates it from SSRIs and SNRIs pharmacologically.

5-HT2A Antagonism and Sleep Architecture

The sedative properties that make trazodone so widely prescribed for insomnia stem primarily from its potent 5-HT2A blockade, combined with histamine H1 receptor antagonism and alpha-1 adrenergic blockade [2]. At low doses (25 to 100 mg), antihistamine and 5-HT2A effects dominate. Serotonin reuptake inhibition becomes clinically meaningful only at higher antidepressant doses (150 to 600 mg daily), which is why the monitoring burden increases with dose.

The mCPP Metabolite

CYP3A4 converts trazodone into meta-chlorophenylpiperazine (mCPP), a metabolite with serotonin agonist properties that can cause anxiety, dysphoria, and headache in some patients [3]. Drugs that inhibit CYP3A4 (ritonavir, ketoconazole, clarithromycin) raise trazodone levels and reduce mCPP formation. CYP3A4 inducers (carbamazepine, phenytoin) do the opposite. These interactions shape what labs matter and when.

Why the Mechanism Dictates the Monitoring Schedule

Each receptor target carries a monitoring implication. Alpha-1 blockade causes orthostatic hypotension, making blood pressure checks mandatory. Serotonin modulation raises SIADH and hyponatremia risk. QTc prolongation appears dose-dependent in post-marketing data [4]. A prescriber who understands these pharmacologic pathways orders the right tests at the right time.

Baseline Labs Before Starting Trazodone

Every patient starting trazodone needs a defined set of labs and exams before the first dose. Skipping baseline values makes it impossible to attribute later abnormalities to the drug versus pre-existing pathology.

Comprehensive Metabolic Panel (CMP)

The CMP captures hepatic transaminases (AST, ALT), renal function (BUN, creatinine, eGFR), electrolytes, and fasting glucose. Trazodone undergoes extensive hepatic metabolism via CYP3A4, so liver impairment changes drug exposure [3]. Baseline sodium is especially relevant: SIADH-related hyponatremia is a recognized adverse effect of serotonergic antidepressants, and the FDA prescribing information lists it as a warning [4].

Complete Blood Count (CBC) with Differential

Case reports have linked trazodone to rare hematologic effects including leukopenia and neutropenia [5]. A baseline CBC with differential provides a reference point. This is standard practice across serotonergic antidepressants per the American Psychiatric Association (APA) practice guidelines.

Thyroid Function (TSH)

Thyroid dysfunction mimics and exacerbates both depression and insomnia. The APA recommends TSH screening before initiating any antidepressant to rule out hypothyroidism as a contributing or confounding factor [6]. This is not trazodone-specific but remains part of the standard workup.

Electrocardiogram (ECG)

The FDA label warns about QT prolongation and reports of torsades de pointes, particularly in overdose and in patients taking concomitant QT-prolonging medications [4]. A baseline 12-lead ECG is recommended for patients over 50, those with cardiac history, and anyone on other QTc-prolonging drugs. The American Heart Association consensus statement on drug-induced QTc prolongation supports pre-treatment ECG in moderate-risk scenarios [7].

Orthostatic Vital Signs

Alpha-1 adrenergic blockade makes orthostatic hypotension one of the most common trazodone side effects, with fall risk increasing in elderly patients. Lying and standing blood pressure readings at baseline take 3 minutes and can prevent a hip fracture.

The 4-to-6-Week Follow-Up Panel

The first recheck occurs 4 to 6 weeks after initiation or any dose increase. This timing aligns with steady-state pharmacokinetics (trazodone half-life is 5 to 9 hours, but clinical effects and side effects may evolve over weeks) and with the antidepressant response timeline.

What to Recheck

Repeat the CMP with particular attention to sodium. A serum sodium drop of 5 mEq/L or more from baseline, even if still within the normal range, should prompt closer surveillance. Repeat the CBC if the baseline showed any borderline values. Repeat the ECG if the starting QTc was above 440 ms in men or 460 ms in women, or if the dose has been titrated above 300 mg daily.

Suicide Risk Assessment

The FDA black box warning on all antidepressants requires close monitoring for suicidal ideation, especially in patients under 25 [4]. The Columbia Suicide Severity Rating Scale (C-SSRS) should be administered at baseline and at each follow-up during the first 12 weeks. This is a clinical assessment, not a lab, but it belongs on the monitoring checklist.

Blood Pressure and Heart Rate

Recheck orthostatic vitals at every visit during titration. A systolic drop of 20 mmHg or more on standing meets criteria for orthostatic hypotension and may require dose reduction, slower titration, or hydration counseling.

Ongoing Monitoring: The 6-to-12-Month Cycle

Once a patient reaches a stable dose with no adverse findings at the 4-to-6-week check, the monitoring interval extends to every 6 to 12 months. The exact frequency depends on patient age, comorbidities, and concomitant medications.

Standard Annual Labs

| Test | Frequency | Rationale | |------|-----------|-----------| | CMP (including sodium) | Every 6 to 12 months | Hepatic function, renal function, SIADH screening | | CBC with differential | Annually | Hematologic surveillance | | TSH | Annually | Thyroid function co-monitoring | | Fasting lipids and glucose | Annually | Metabolic health (especially if weight changes occur) | | ECG | Annually if on doses above 300 mg or QTc risk factors | QTc surveillance |

Sodium Monitoring in Older Adults

Hyponatremia from SIADH is the single most clinically significant lab abnormality associated with trazodone in patients over 65. A retrospective analysis published in the Journal of Clinical Psychopharmacology found that antidepressant-associated hyponatremia occurred in approximately 5% of elderly patients on serotonergic agents, with onset typically within the first 2 to 4 weeks [8]. For patients 65 and older, checking sodium at 2 weeks, 4 weeks, and then quarterly for the first year is a reasonable protocol.

When to Order Extra Labs

Unscheduled lab draws are warranted if a patient develops new confusion, lethargy, nausea, or seizure (hyponatremia); unexplained bruising or recurrent infections (hematologic); jaundice or right-upper-quadrant pain (hepatic); or syncope, palpitations, or new dizziness (cardiac). Do not wait for the next scheduled panel.

Cardiac Monitoring: QTc and Beyond

Trazodone's QTc effect is dose-dependent. At antidepressant doses (150 to 600 mg), the risk is clinically relevant enough to track, especially in combination with other QT-prolonging agents.

QTc Thresholds That Trigger Action

The FDA safety communication on citalopram QTc risk (2012) established a broadly applied framework: a QTc above 500 ms or an increase of 60 ms or more from baseline warrants discontinuation or dose reduction [9]. Most cardiologists and psychiatrists apply these same thresholds to trazodone.

Who Needs Serial ECGs

Patients on trazodone doses above 300 mg daily, those co-prescribed methadone, antipsychotics, or fluoroquinolones, patients with heart failure or bradycardia, and anyone with a baseline QTc above 450 ms should receive ECGs at baseline, 4 to 6 weeks, and then every 6 to 12 months. A Mendelson (2005) review noted that while trazodone's off-label sleep use is widespread, systematic cardiac monitoring data in this population remains sparse [1].

Practical QTc Decision Tree

• QTc <450 ms at baseline: proceed with standard monitoring
• QTc 450 to 470 ms: obtain repeat ECG in 2 weeks after initiation; avoid QT-prolonging co-prescriptions if possible
• QTc 470 to 500 ms: consider alternative hypnotic or antidepressant; if trazodone is clinically necessary, repeat ECG within 1 week of each dose change
• QTc >500 ms: do not initiate trazodone; if already on it, taper and discontinue

Hepatic and Renal Considerations

Trazodone is extensively metabolized by the liver and should be used cautiously in hepatic impairment. Renal excretion accounts for approximately 75% of elimination (mostly as metabolites), with less than 1% excreted unchanged [3].

Liver Function Monitoring

The FDA label recommends caution in hepatic disease without specifying exact dose adjustments [4]. In practice, clinicians start at 50% of the usual dose in Child-Pugh class B or C patients and check hepatic transaminases every 4 to 6 weeks for the first 3 months.

Renal Function Monitoring

Mild to moderate renal impairment (eGFR 30 to 89 mL/min) does not typically require dose modification, but severe impairment (eGFR <30 mL/min) warrants closer monitoring of drug levels and metabolite accumulation. Creatinine and eGFR should be part of the standard CMP at every check.

Special Populations and Adjusted Monitoring

Patients Over 65

The elderly face compounded risks: higher SIADH rates, greater orthostatic hypotension, increased fall risk, and more frequent polypharmacy creating drug interactions. The American Geriatrics Society Beers Criteria does not list trazodone as a drug to avoid, but it flags the need for careful orthostatic monitoring and sodium surveillance in this age group [10]. Recommended schedule for patients over 65:

• Sodium at 2 weeks, 4 weeks, 8 weeks, then quarterly
• Orthostatic vitals at every visit
• ECG at baseline and 6 months
• Fall risk assessment at each visit using a validated tool (e.g., Timed Up and Go)

Patients Under 25

The FDA black box warning mandates weekly face-to-face or telehealth visits for the first 4 weeks, biweekly for weeks 5 through 12, and then as clinically indicated [4]. Document C-SSRS scores at each contact. Lab monitoring follows the standard adult schedule.

Pregnancy and Lactation

Trazodone is FDA pregnancy category C. No adequate controlled studies exist in pregnant women. If prescribed during pregnancy, the monitoring schedule should include serial fetal ultrasounds and neonatal observation for serotonergic effects (poor adaptation syndrome) after delivery. The National Institutes of Health LactMed database notes limited data on trazodone in breast milk, with low relative infant doses reported [11].

Drug Interactions That Change the Monitoring Plan

CYP3A4 Inhibitors

Co-administration with strong CYP3A4 inhibitors (ritonavir, itraconazole, clarithromycin) can increase trazodone AUC by 2-fold or more [3]. When adding a CYP3A4 inhibitor to existing trazodone therapy, reduce the trazodone dose by 50% and recheck labs (CMP, ECG) within 1 to 2 weeks.

Serotonergic Drugs

Combining trazodone with SSRIs, SNRIs, tramadol, triptans, or MAOIs increases serotonin syndrome risk. The Hunter Serotonin Toxicity Criteria provide a diagnostic framework [12]. No lab test diagnoses serotonin syndrome, but a CK level helps rule out rhabdomyolysis in suspected cases. Clinical assessment (clonus, agitation, hyperthermia, hyperreflexia) is the monitoring tool.

QT-Prolonging Co-Medications

When trazodone is combined with methadone, antipsychotics (haloperidol, ziprasidone), ondansetron, or fluoroquinolones, obtain a baseline ECG before adding the second agent and repeat at 1 week and 4 weeks. A QTc increase of 30 ms or more from the pre-combination baseline triggers dose re-evaluation.

Putting It Together: A Consolidated Monitoring Timeline

| Timepoint | Labs & Assessments | |-----------|-------------------| | Baseline (pre-dose) | CMP, CBC w/diff, TSH, ECG (if indicated), orthostatic vitals, C-SSRS, medication reconciliation for interactions | | 2 weeks | Sodium (if age 65+ or hyponatremia risk), orthostatic vitals, C-SSRS (if age <25), clinical assessment | | 4 to 6 weeks | CMP, CBC (if baseline borderline), ECG (if dose above 300 mg or QTc risk), orthostatic vitals, C-SSRS | | 3 months | Clinical assessment, orthostatic vitals, sodium recheck (if 65+) | | 6 months | CMP, orthostatic vitals, ECG (if on high dose or QTc risk) | | 12 months and annually | CMP, CBC, TSH, fasting lipids/glucose, ECG (if indicated), fall risk (if 65+) | | Any dose change | Repeat the 4-to-6-week protocol from the new dose start date |

According to the APA Practice Guidelines for Major Depressive Disorder (2010), "Laboratory monitoring should be individualized based on the specific medication's side-effect profile, patient age, and medical comorbidities" [6]. Trazodone's side-effect profile makes sodium, hepatic function, and QTc the three pillars of ongoing surveillance.

The Endocrine Society recommends that clinicians "check serum sodium within the first few weeks of starting or increasing the dose of any serotonergic antidepressant in patients with risk factors for hyponatremia" [13]. For trazodone, those risk factors include age over 65, concurrent diuretic use, low baseline sodium, and low body weight.